Endotelioand cardioprotective effects of HMG-Co-A reductase in endotoksininducing endotelial dysfunction

Кубанский научный медицинский вестник

O. A. Osipova¹  M. V. Pokrovskii¹  M. V. Korokin¹  O. S. Gudyrev¹  T. A. Denisuk¹  T. G. Pokrovskaya¹  O. V. Philippova¹ 

[1] FSAEI VPO «BSU», SEI HPE KSMU of Russian ministry of health;

关键词: дисфункция эндотелия;    ингибиторы гмг-ко-а-редуктазы симвастатин;    аторвастатин;    розу-вастатин;    эндотоксин;    endothelial dysfunction;    hmg-co-a-reductase inhibitor simvastatin;    atorvastatin;    rosuvastatin;    endotoxin;   

DOI  :  10.25207/1608-6228-2015-5-51-55

来源: DOAJ

【 摘 要 】

The use of inhibitors of HMG-Co-A reductase inhibitor simvastatin, atorvastatin, rosuvastatin and nanoparticulative rosuvastatin on background modeling endotoksininducing pathology, introduction of strain 603 Staphylococcusaureus leads to the development of dose-response endotelioprotectiv action, expressed in the normalization of QED, prevent increase adrenoreactivity and exhaustion of myocardial reserve and and normalization of biochemical markers of inflammation (C-reactive protein) and the level of proinflammatory cytokines. When this is detected positive dynamics and-products of NO and expression of eNOS.

【 授权许可】

Unknown